



DENTAL TRIBUNE

The World's Dental Newspaper • Middle East & Africa Edition


Printed in Dubai

www.dental-tribune.me

September-October 2015 | No. 5, Vol. 4

ENDO TRIBUNE

Diagnosis and management of a rare case of a maxillary second molar with two palatal roots



>Insertion

HYGIENE TRIBUNE


iTOP - Harp instead of rock guitar



>Insertion

LAB TRIBUNE

Discovering the world of dental ceramics



>Insertion

Middle East's Dentist Meet Recommends Power Brushes for Improved Oral Hygiene

By Oral-B

DUBAI, UAE: First dental consensus agrees that electric power brushing is best for oral health; 80 per cent of children between 12-15 years have unhealthy gums, according to research by the Dubai Healthcare Authority.

A group of the Middle East's leading dentists have come together to agree on

how best to promote good oral hygiene through brushing. Held in Dubai at the end of August and supported by Procter & Gamble, the first dental consensus has issued a series of recommendations to help improve oral hygiene in the region. These proposals, which focused on tooth brushing habits across the Middle East, include an agreement that electric power brushes are more effective at maintaining oral health, and that Bluetooth enabled power brushes have the potential



Dr. Ashhad Kazi, Dr. Nabih Nader, Dr. Montasser Al-Qutub, Prof. Khaled Balto, Dr. Ajay Juneja, Dr. Nabeel Al-Sabeeha, Dr. Efthérios Kakkamanos, Bottom row left to right: Dr. Elias Berdouses, Dr. Arwa Al-Sayed, Prof. Crawford Bain, Dr. Ekaterina Fabrikant, Dr. Badar Monir Zaki

SOUTHERNIMPLANTS

MAX Implants

Co-Axis Implants

May Eliminate The Need For Grafting
Shortens Treatment Time

Appropriate Emergence

Stable Enough For Immediate Restoration

5 Different Connections



NEWS

Counterfeit KaVo branded dental... 2
Read more... 40-42

MEDIA CME

Use and abuse of antibiotics 6
Read more... 7-12

ORAL HEALTH

Mirror mirror on the wall... 15
Read more... 14-19

INDUSTRY

Welcome to the world of ... 24
Read more... 25

ORTHO TRIBUNE

A new era in digital orthodontics... 26-27

IMPLANT TRIBUNE

"One miracle at a time"... 28-50
Read more... 35-56

REFERRAL CLINIC

SameDay® molar implant... 31-54

INTERVIEW

Restoring a back to basic approach 38-59

PRACTICE MANAGEMENT

The Road Map to Customer 44
Read more... 46

to encourage better oral care among children.

Co-chaired by Dubai's Hamdan Bin Mohammed College of Dental Medicine's Professor Crawford Bain and Dr. Arwa Al-Sayed, Head of the Periodontics and Implants Department at Prince Sultan Military Medical City in Riyadh, the ten dentists from Lebanon, Oman, Saudi Arabia and the United Arab Emirates met for two days to discuss how best to promote better brushing habits among the region's consumers. Research undertaken by the Dubai Healthcare Authority in February of this year showed that 80 percent of children in Dubai between the ages of 12 and 15 have unhealthy gums.

The group agreed on the following recommendations:

1. Evidence suggests that power brushes are more effective in the short & long term compared to manual brushes. According to present data, over the short & long term, power brushes are better at maintaining oral health.
2. Evidence suggests that oscillating-rotating power brushes are superior to all

> Page 41

CAREERS

- Career Opportunities
- Job openings
- Dental Categories

www.dental-tribune.com/careers

P.O. BOX 505190, DUBAI, U.A.E.
Tel: +971 (0)56 131 1574
Fax: +971 (0)4 427 5011

info@southernimplants.net | www.southernimplants.com

Counterfeit KaVo branded dental turbines may pose severe risks to the dental practice



By KaVo

In the last year the dental market has witnessed a high increase in the number of counterfeit KaVo branded turbines and replacement parts.

KaVo has identified counterfeit turbines and parts in several different countries and sales channels. The fake turbines are of unknown origin and are poorly constructed items. The counterfeit parts are also untraceable, are not manufactured to KaVo's quality standards and their use

will void the product warranty. The turbines and parts were most likely not tested for safety, quality or effectiveness and could fail during use with a risk of injury to patient and user. We highlight below several critical product issues which bear elevated risks for patients, dentist and dealers:

- The CE label is counterfeit; so these products are not proven medical devices that were tested for safety and effectiveness;
- With no official manufacturer, there is no organization respon-



DENTAL TRIBUNE

GROUP EDITOR
Daniel Zimmermann
newsroom@dental-tribune.com
Tel.: +49 541 48 474 107

CLINICAL EDITOR
Magda Wojtkiewicz

ONLINE EDITOR
SOCIAL MEDIA MANAGER
Claudia Duschek

EDITORIAL ASSISTANTS
Anne Faulmann
Kristin Hübner

COPY EDITORS
Sabrina Raaff
Hans Motschmann

PUBLISHER/PRESIDENT/CEO
Torsten Oemus

CHIEF FINANCIAL OFFICER
Dan Wunderlich

CHIEF TECHNOLOGY OFFICER
Serban Veres

BUSINESS DEVELOPMENT MANAGER
Claudia Salwiczek

JUNIOR MANAGER BUSINESS DEVELOPMENT
Sarah Schubert

PROJECT MANAGER ONLINE
Tom Carvalho

EDUCATION MANAGER
Christiane Ferret

EVENT MANAGER
Lars Hoffmann

MARKETING & SALES SERVICES
Nicole Andra

EVENT SERVICES
Esther Wodarski

ACCOUNTING SERVICES
Karen Hamatschek
Anja Maywald
Manuela Hunger

MEDIA SALES MANAGERS
Matthias Diessner (Key Accounts)
Melissa Brown (International)
Antje Kahnt (International)
Peter Witteczek (Asia Pacific)
Weridiana Magowski (Latin America)
Maria Kaiser (USA)
Hélène Carpentier (Europe)
Barbora Solarova (Eastern Europe)

EXECUTIVE PRODUCER
Gernot Meyer

ADVERTISING DISPOSITION
Marius Mezger

DENTAL TRIBUNE INTERNATIONAL
Holbeinstr. 29, 04229 Leipzig, Germany
Tel.: +49 541 48 474 502
Fax: +49 541 48 474 175
www.dental-tribune.com
info@dental-tribune.com

DENTAL TRIBUNE ASIA PACIFIC LTD.
Room A, 20/F
Harvard Commercial Building
105-111 Thomson Road, Wanchai, HK
Tel.: +852 5115 6177
Fax: +852 5115 6199

THE AMERICA, LLC
116 West 25rd Street, Ste. 500, New York
N.Y. 10011, USA
Tel.: +1 212 244 7181
Fax: +1 212 244 7185

DENTAL TRIBUNE MEA EDITION EDITORIAL BOARD
Dr. Aisha Sultan Alsuwaidi, UAE
Dr. Ninette Banday, UAE
Dr. Nabeel Humood Alsabeeha, UAE
Dr. Mohammad Al-Obaida, KSA
Dr. Meshari F. Alotaibi, KSA
Dr. Jasim M. Al-Saeedi, Oman
Dr. Mohammed Sultan Al-Darwish
Prof. Khaled Balto, KSA
Dr. Dobrina Mollova, UAE
Dr. Munir Silvadi, UAE
Dr. Khaled Abouseada, KSA
Dr. Rabih Abi Nader, UAE
Dr. George Sanoop, UAE
Aiham Farrah, CDT, UAE
Retty M. Matthew, UAE
Rodny Abdallah, CDT, Lebanon

PARTNERS
Emirates Dental Society
Saudi Dental Society
Lebanese Dental Association
Qatar Dental Society
Oman Dental Society

DIRECTOR OF mCME
Dr. Dobrina Mollova
mollova@dental-tribune.me
Tel.: +971 50 42 45072

DIRECTOR
Tzvetan Deyanov
deyanov@dental-tribune.me
Tel.: +971 55 11 28 581

DESIGNER
Kinga Romik
k.romik@dental-tribune.me

KaVo ESTETICA E70/E80 Vision

ESTETICA E70/E80 Vision

Get in touch with your vision.

We strive to work with you to find the best solution for your patients' needs.
Contact us: info.mea@kavo.com or visit us: www.kavo.com

Download the Brochure Now!



High Resolution Screen
KaVo HD screen: 22 inches
KaVo Screen One: 19 inches



Individual Configuration

Hygienic
Automated hygiene programs with easy-to-clean components.

Comfortable & Simple
The new armrests make it easier for your patients to step on and off the chair.



Efficient Workflow
Touchscreen display & control panel, redesigned with user interface for intuitive & easy operation of all important functions.



KaVo. Dental Excellence.

KaVo Dental GmbH · D-88400 Biberach/Riß · Telefon +49 7351 56-0 · Fax +49 7351 56-1488 · www.kavo.com

sible for these items or any warranty claims;

- The counterfeit turbines use the outdated COMPACTorque design rather than the current SMARTorque design that was launched in 2013;
- Dealers, who trade in counterfeit KaVo turbines in the EU are responsible for any claims and may face legal consequences.

In January 2014, the Medicines and Healthcare Products Regulatory Agency even issued a warning to dentists after a counterfeit product shattered while being used on a patient. For all the above reasons, KaVo is advising dealers to not buy or sell these counterfeit turbines and warning dentists to not use them for patients' treatment.

Identifying the Counterfeit Products

In an effort to deceive buyers, the fake products have exactly the same packaging as the genuine KaVo turbines with a forged "SMARTcover" wrapped around a black box. Furthermore, many of the counterfeit turbines use the same serial number (SN 11-0505000). If you encounter a product with serial number SN-11-0505000 it is almost certainly counterfeit and should be discontinued. In some instances the product description in the user manual differs from the printed name on the turbine. Many of the counterfeit items also use a false name "COMPACTorque 660B" and the user manual, in most instances, is for a different product, the Unik Midwest Turbine. Therefore the REF. number on the product label doesn't match with the REF. number on the user manual.

SMALL CHANGE. BIG DIFFERENCE.

The new imaging plate scanner XIOS Scan completes the intraoral family from Sirona. Whether you're taking the first steps into the digital world or establishing or updating a fully digital practice, XIOS Scan and XIOS XG Sensors offer perfectly synchronized solutions for every-workflow. **Enjoy every day. With Sirona.**



THE NEW
IMAGING PLATE
SCANNER:
XIOS Scan

SIRONA.COM

The Dental Company

sirona.

Ketac™ Universal Aplicap™ Glass Ionomer Restorative Clinical Case

By Dr. Jacqueline Esch, Germany

Treatment of a 6-year old patient under general anaesthesia with caries on deciduous mandibular molars.

About the Author

Dr. Jacqueline Esch
Specialist in pediatric and adolescent dentistry of German Society for Oral and Maxillofacial Surgery (DG-ZMK), co-founder of group practices 'International practice for pediatric dentistry and orthodontics' ('Internationale Praxis für Kinderzahnheilkunde und Kieferorthopädie'), Munich. Board member of the Federal Association of Pediatric Dentists (BUKIZ). Head of Training Centre for Child and Adolescent Dentistry in Munich.




Fig.1. X-ray of deciduous teeth. Proximal lesion visible.



Fig.2. Initial situation: primary first and second molar with carious lesions



Fig.3. Caries removal. Minimally invasive preparation: caries-free areas of enamel and dentine are left in the center of the cavity



Fig.4. Placement of Tofflemire matrix



Fig.5. Bulk placement of Ketac™ Universal Aplicap™ into cavity



Fig.6. Shaping of the occlusal surface



Fig.7. Surface adjustment and excess removal with a fine diamond bur



Fig.8. Polishing of the occlusal surface with Sof-Lex™ Spiral Polishing Wheels



Fig.9. Final Ketac™ Universal Glass Ionomer restorations

Ketac™ Universal Aplicap™ Restorative. Dentist satisfaction ratings.

By 3M

In an application test, 965 fillings were placed using Ketac Universal Aplicap restorative. Dentists were pleased with time savings, overall handling, ease of placement and cavity adaptation¹. [DT](#)

94%
verified it enables an easy 1-step placement

84%
agreed the NEW design of the nozzle leads to better access to deep cavities

75%
stated that the low stickiness to instruments allows easy placement

¹. Source: Please refer to the Technical Data Sheet



Finish faster. Finish strong.

Now, get them out of the chair faster!

Pediatric. Geriatric. And busy teens in between. Treating patients who can't sit still long feels like a race against the clock—and every second counts. That's why 3M ESPE Dental developed Ketac™ Universal Aplicap™ Glass Ionomer Restorative.

- **One-step placement**—no conditioning, coating or light-curing steps to slow the procedure down
- **Stress-bearing properties** enable extended indications
- **Continuous fluoride release** over 12 months

Ketac Universal restorative ... because the most caries-prone patients are also the most restless.

For more information please visit:

www.3MGulf.com/espe



**Ketac™
Universal
Aplicap™**

Glass Ionomer Restorative

3M

Use and abuse of antibiotics



*mCME articles in Dental Tribune have been approved by:
HAAD as having educational content for 2 CME Credit Hours
DHA awarded this program for 2 CPD Credit Points*

ADA CERP® | Continuing Education Recognition Program

Centre for Advanced Professional Practices (CAPP) is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.

CAPPmea designates this activity for 2 continuing education credits.

By Steven G. Morrow, USA

For the past 80 years, antibiotic therapy has played a major role in the treatment of bacterial infectious diseases. Since the discovery of penicillin in 1928 by Fleming and sulfanilamide in 1934 by Domagk, the entire world has benefited from one of the greatest medical advancements in history. The discovery of safe, systemic antibiotics has been a major factor in the control of infectious diseases and, as such, has increased life expectancy and the quality of life for millions of people.

According to the Centers for Disease Control and Prevention, life expectancy of individuals in the United States born in 1900 was 47 years, while those born in 2005 is projected to be 78 years.¹ At the beginning of the 20th century, the infant (< 1 year) mortality rate in the United States was 100/1,000 live births compared to 6.7/1,000 in 2006.² The major reason for these phenomenal achievements has been the ability to control infectious diseases.³

Development of antibacterial drug resistance

Along with the dramatic benefits of systemic antibiotics, there has also been an explosion in the number of bacteria that have become resistant to a variety of these drugs. The problem is not the antibiotics themselves. They remain one of medicine's most potent weapons against diseases. Instead, the problem is in the way the drugs are used. The inappropriate overuse of antibiotics has resulted in a crisis situation due to bacterial mutations developing resistant strains.

Many worldwide strains of *Staphylococcus aureus* exhibit resistance to all medically important antibacterial drugs, including vancomycin; and methicillin-resistant *S. aureus* has become one of the most frequent nosocomial, or hospital-acquired, pathogens. The rate at which bacteria develop re-

sistance to antibacterial drugs is alarming, demonstrating resistance soon after new drugs have been introduced. This rapid development of resistance has contributed significantly to the morbidity and mortality of infectious diseases, especially nosocomial infections.⁴

A nosocomial infection is a hospital-acquired infection that develops in a patient after admission. It is usually defined as an infection that is identified at least 48 to 72 hours following admission, so infections incubating, but not clinically apparent at admission, are excluded. Nosocomial infections are costly, resulting in increased morbidity, requiring longer periods of hospitalization and limiting access of other patients to hospital resources. The direct costs of hospital-acquired infections in the United States are estimated to be \$4.5 billion per year. Nosocomial infections also contribute to the emergence and dissemination of antimicrobial-resistant organisms. Antimicrobial use for treatment or prevention of infections facilitates the emergence of more resistant organisms. Patients with infections caused by antimicrobial-resistant organisms are then a source of infection for hospital staff and other hospitalized patients. These drug-resistant infections may subsequently spread to the community.⁵

The British Society for Antimicrobial Chemotherapy published a review in the *Journal of Antimicrobial Chemotherapy*. This review examined the contributions antibiotic prescribing by general dentists in the United Kingdom has made to the selection of antibiotic resistance in bacteria of the oral flora.⁶ The review concluded that inappropriate antibacterial drug prescribing by dental practitioners is a significant contributing factor in the selection of drug-resistant bacterial strains. The American Dental Association reported the results of a survey of antibiotic use in dentistry in the November 2000 *Journal of the American Dental Association*.⁷ The authors



Fig. 1. Asymptomatic apical periodontitis. (Photos/Provided by American Association of Endodontists)



Fig. 2. Chronic apical abscess.



Fig. 3. Acute apical abscess with intraoral localized swelling.

surveyed all licensed dentists practicing in Canada and found that confusion about prescribing antibiotics and inappropriate prescribing practices were evident, and that inappropriate antibiotic use, such as improper dosing, duration of therapy and prophylaxis are all factors that may affect development of antibiotic resistant microorganisms.

There is a glimmer of hope

A report from Aker University in Oslo, Norway, strongly suggests that bacterial resistance to antibacterial agents can be reversed.⁸ While dangerous and contagious staph infections kill thousands of patients in the most sophisticated hospitals in Europe, North America and Asia, there is virtually no sign of this "killer superbug" in Norway. The reason? Norway stopped using so many antibiotics.

"We don't throw antibiotics at every person with a fever. We tell them to hang on, wait and see, and we give them a Tylenol to feel better," said Dr. John Haug, infectious disease specialist at Aker University Hospital.⁸ In Norway's simple solution, there is a glimmer of hope.

The proper clinical use of antibacterial drugs

In 1997, the ADA Council on Scientific Affairs issued a position statement on Antibiotic Use in Dentistry.⁹ The Council stated: "Microbial resistance to antibiotics is increasing at an alarming rate. The major cause of this public health problem is

the use of antibiotics in an inappropriate manner, leading to the selection of dominance of resistant microorganisms and/or the increased transfer of resistance genes from antibiotic-resistant to antibiotic-susceptible microorganisms."⁹

The council's position statement further identified that "Antibiotics are properly employed only for the management of active infectious disease or the prevention of metastatic infection, such as infective endocarditis, in medically high-risk patients."⁹ One method of education is to teach from errors rather than principles. Psychologists from the University of Exeter have identified an "early warning signal" in the brain that helps us avoid repeating previous mistakes. Published in the *Journal of Cognitive Neuroscience*,¹⁰ their research identifies for the first time, a mechanism in the brain that reacts, in just one-tenth of a second, to things that have resulted in us making errors in the past. Evaluating the following eight misconceptions or "myths" may help to establish general guidelines to aid us in making clinical decisions regarding the use of antibiotic therapy, thereby leading to optimum use and therapeutic success.¹¹

Myth No. 1: Antibiotics cure patients. Except in patients with a compromised immune system, antibiotics are not curative, but instead function to assist in the re-establishment of the proper balance between the host's de-

fenses (immune and inflammatory) and the invasive agent(s). Antibiotics do not cure patients; patients cure themselves.

Myth No. 2: Antibiotics are substitutes for surgical intervention. Very seldom are antibiotics an appropriate substitute for removal of the source of the infection (extraction, endodontic treatment, incision and drainage, periodontal scaling and root planing). Occasionally, when the infection is too diffuse or disseminated to identify a nidus for incision, or the clinical situation does not allow for immediate curative treatment, the prudent dentist will choose to place the patient on appropriate antibacterial therapy until such time as curative treatment can be implemented. It is imperative to remove the cause of the infection prior to, or concomitant with, antibiotic therapy, when the cause is readily identifiable. Whenever antibiotic therapy is used, the risk of bacterial selection for antibiotic resistance is present.

Myth No. 3: The most important decision is which antibiotic to use. To avoid the deleterious effects of needless antibiotics on patients and the environment, the most important initial decision is not which antibiotic to prescribe but whether to use one at all. It has been estimated that up to 60 percent of human infections resolve by host defenses alone following removal of the cause of the infection without antibiotic intervention. Endodontic disease is infectious. Microorganisms cause virtually all pathoses of the pulp and periapical tissues. There is ample evidence to support that opportunistic normal oral microbiota colonize in a symbiotic relationship with the host, resulting in endodontic infections.¹² The majority of endodontic infections do not require systemic antibiotic therapy when the cause of the infection

Primary Reasons for Revision of Infective Endocarditis Guidelines

1. IE is much more likely to result from frequent exposure to random bacteremias associated with daily activities than from bacteremias caused by a dental, GI tract or GU tract procedure.
2. Prophylaxis may prevent an exceedingly small number of cases of IE, if any, in individuals who undergo a dental, GI tract or GU tract procedure.
3. The risk of antibiotic-associated adverse events exceeds the benefit, if any, from prophylactic antibiotic therapy.
4. Maintenance of optimal oral health and hygiene may reduce the incidence of bacteremia from daily activities and is more important than prophylactic antibiotics for a dental procedure to reduce the risk of IE.

Table 1. (Tables/Provided by American Association of Endodontists)



Medical Conditions for Which Endocarditis Prophylaxis is Recommended:

Premedication is recommended **ONLY** for patients with the following conditions associated with the highest risk of adverse outcomes from endocarditis:

1. Prosthetic cardiac/heart valve.
2. History of IE.
3. Cardiac transplant recipients who develop valve pathology.
4. One of the following congenital heart diseases:
 - Unrepaired cyanotic CHD, including palliative shunts and conduits.
 - Completely repaired congenital heart defects with prosthetic material or device, whether placed by surgery or by catheter intervention, **during the first six months after placement of the material or device (because endothelialization of prosthetic material occurs within six months after the procedure).**
 - Repaired CHD with residual defects at, or adjacent to, the site of a prosthetic patch or prosthetic device (which inhibits endothelialization).
5. Special situations and circumstances:
 - **Patients already receiving antibiotics**—Occasionally, a patient may be taking an antibiotic when coming for a dental appointment. If the patient is taking an antibiotic normally used for endocarditis prophylaxis, it is prudent to select a drug from a different class rather than increase the dose of the current antibiotic. If possible, you should delay the dental procedure until at least 10 days after completion of the antibiotic. This will allow for the usual oral flora to be re-established. If an individual receiving long-term parenteral antibiotic therapy for IE requires dental treatment, the treatment should be timed to occur 30 to 60 minutes after the parenteral antibiotic therapy has been delivered.
 - **Failure to administer pretreatment antibiotic dose**—If the dosage of an antibiotic is inadvertently not administered before the procedure, the dosage may be administered up to two hours after the procedure. However, administration of the dosage after the procedure should be considered only when the patient did not receive the preprocedure dose.
 - **Individuals with kidney dialysis shunts**—Individuals with permanent kidney dialysis shunts should be placed on prophylactic antibiotics using the same protocol as for IE.

Table 2. (Tables/Provided by American Association of Endodontists)

has been properly managed (complete debridement of the pulp space and proper obturation and sealing of the pulp space from the oral environment).

Apical periodontitis lesions of pulpal origin are generated by the immune system and are the result of intraradicular infections (Fig. 1). In most situations, this inflammatory process successfully eliminates the bacteria emerging from the apical foramen and prevents their spread to the periapical tissues. This process is primarily facilitated by the polymorphonuclear leukocytes that eventually phagocytize and kill the bacteria.¹⁵ Asymptomatic apical periodontitis of pulpal origin does not routinely require systemic antibiotic therapy for satisfactory resolution and healing. Endodontic therapy alone is usually sufficient.

When the intraradicular infection is able to overwhelm the host's immune response, viable bacteria are able to gain access to the periapical tissues and colonize, forming an active

infection. This results in the formation of an apical abscess. A chronic apical abscess usually presents with gradual onset, no to mild symptoms and the presence of a sinus tract or parulis (Fig. 2). The majority of chronic apical abscesses of endodontic origin do not require systemic antibiotic therapy for satisfactory resolution and healing.

An acute apical abscess usually presents with rapid onset, spontaneous pain and swelling, both localized and intraoral, sometimes with exudate present, or with diffuse facial cellulitis. When the abscess is intraoral and localized (Fig. 3), debridement of the pulp space and placement of calcium hydroxide and surgical incision for drainage is usually sufficient to resolve the problem. Systemic antibiotic therapy is not routinely indicated, depending on the patient's general medical status. However, when the patient presents with diffuse facial swelling (cellulitis) resulting from an acute apical abscess or an infection with systemic involvement (fever or malaise) (Fig. 4), debridement of the pulp space

with placement of calcium hydroxide, surgical incision for drainage, when possible, and an appropriate regimen of systemic antibiotics (oral or IV) are the treatments of choice.

Understanding the enemy is an important factor in winning any battle. The rational choice and use of antimicrobial agents begins with the knowledge of the microorganisms most likely responsible for common dental infections of pulpal origin. The bacterial flora found in endodontic infections is indigenous, mixed (Gram-positive and Gram-negative) and predominantly anaerobic. Several species have been implicated with acute apical abscesses. These species include dark-pigmented bacteria (*Prevotella* and *Porphyromonas*), eubacteria, fusobacteria and *Actinomyces*.¹²

Baumgartner and Xia published a report of the susceptibility of bacteria recovered from acute apical abscesses to five commonly used antibiotics in dentistry. Antibiotic susceptibility data from 98 species of bacteria recovered from 12 acute apical abscesses led to the following conclusions:

1. Pen-V-K is the antibiotic of choice for endodontic infections due to its effectiveness in polymicrobial infections, its relative narrow spectrum of activity against bacteria most commonly found in endodontic infections, its low toxicity and low cost.
2. Clindamycin is the antibiotic of choice for patients allergic to penicillins.
3. While amoxicillin and augmentin (amoxicillin plus clavulanate) demonstrated a higher antibacterial effectiveness than Pen-V-K, due to the broader antibacterial spectrum of amoxicillin and the increased cost of augmentin, the authors rec-

ommended that amoxicillin/augmentin be reserved for unresolved infections and patients who are immunocompromised. 4. Metronidazol demonstrated the greatest amount of bacterial resistance and is only effective against anaerobes. Therefore, it should not be used alone for the treatment of endodontic infections.¹⁴

Myth No. 4: Antibiotics increase

the host's defense to infection. The increased prevalence in organ and tissue transplants, resulting in patients with compromised immune systems, has heightened the interest in the potential effects of antimicrobial drugs on the host's resistance to infection.¹⁵ In vivo and in vitro studies are highly variable and sometimes contradictory. However, the following considerations appear valid: 1) Antibiotics that can penetrate into the mammalian cell (erythromycin, tetracycline, clindamycin and metronidazole) are more likely to affect the host defenses than those that cannot (beta-lactams); 2) Tetracyclines may suppress white cell chemotaxis; 3) Most antibiotics (except tetracycline) do not depress phagocytosis; and 4) T- and B-lymphocyte transformation may be depressed by tetracyclines. The greatest potential harm to the host defenses may result from antibiotics that easily penetrate into the mammalian cell and the least harm is observed with bactericidal, nonpenetrating agents (penicillins and cephalosporins).

Myth No. 5: Multiple antibiotics are superior to a single antibiotic. It is often assumed that a combination of antibiotics is superior to a single carefully chosen antibacterial agent. When the purported benefits of antibiotic combinations are weighed against the possible consequences to the host as well as to the bacterial environment, this assumption is not always reality. The usual sequela to com-

> Page 8



Fig. 4. Acute apical abscess with extraoral diffuse facial cellulitis.

mCME SELF INSTRUCTION PROGRAM

CAPPmea together with Dental Tribune provides the opportunity with its mCME - Self Instruction Program a quick and simple way to meet your continuing education needs. mCME offers you the flexibility to work at your own pace through the material from any location at any time. The content is international, drawn from the upper echelon of dental medicine, but also presents a regional outlook in terms of perspective and subject matter.

Membership:

Yearly membership subscription for mCME: 900 AED
One Time article newspaper subscription: 250 AED per issue.
After the payment, you will receive your membership number and allowing you to start the program.

Completion of mCME

- mCME participants are required to read the continuing medical education (CME) articles published in each issue.
- Each article offers 2 CME Credit and are followed by a quiz Questionnaire online, which is available on <http://www.cappmea.com/mCME/questionnaires.html>.
- Each quiz has to be returned to events@cappmea.com or faxed to: +97143686885 in three months from the publication date.
- A minimum passing score of 80% must be achieved in order to claim credit.
- No more than two answered questions can be submitted at the same time
- Validity of the article - 5 months
- Validity of the subscription - 1 year
- Collection of Credit hours: You will receive the summary report with Certificate, maximum one month after the expiry date of your membership. For single subscription certificates and summary reports will be sent one month after the publication of the article.

The answers and critiques published herein have been checked carefully and represent authoritative opinions about the questions concerned.

Articles are available on www.cappmea.com after the publication. For more information please contact events@cappmea.com or +971 4 3616174

FOR INTERACTION WITH THE AUTHORS FIND THE CONTACT DETAILS AT THE END OF EACH ARTICLE.

Dental Procedures for Which Antibiotic Prophylaxis is Reasonable

- Dental extractions
- Periodontal procedures, including surgery, subgingival placement of antibiotic fibers/strips, scaling and root planing, providing, recall maintenance
- Dental implant placement
- Replantation of avulsed teeth
- Endodontic (root canal) instrumentation only if beyond the root apex and endodontic surgery
- Initial placement of orthodontic bands (not brackets)
- Intraligamentary and intraosseous local anesthetic injections
- Postoperative suture removal (in selected circumstances that may create significant bleeding)
- Prophylactic cleaning of teeth or implants where bleeding is anticipated

Table 3. (Tables/Provided by American Association of Endodontists)

bined antibiotic therapy results in a greater selective pressure on the microbial population to develop drug resistance. The greater the antibacterial spectrum of the antimicrobials used, the greater the number of drug-resistant microorganisms that develop, and the more difficult it is to treat a resulting superinfection. The primary clinical indication for combined antimicrobial therapy is a severe infection in which the offending organism(s) is unknown and major consequences may ensue if antibiotic therapy is not instituted immediately before culture and sensitivity tests are available.⁵

Myth No. 6: Bactericidal agents are always superior to bacteriostatic agents. Bactericidal agents are required for patients with impaired host defenses.⁵ However, bacteriostatic agents are usually satisfactory when the host's defenses against infections are unimpaired. Postantibiotic effects (PAEs — persistent suppression of bacterial growth after previous exposure to antibiotics) are more persistent and reliable with bacteriostatic agents (erythromycin, clindamycin) than with bactericidal agents (beta-lactamase) because the clinical effects of bacteriostatic agents are less dose-dependent.

Myth No. 7: Antibiotic dosages, dosing intervals and duration of therapy are established for most infections. After more than 80 years of antibiotic usage, the proper dosages, dosing intervals and duration of therapy are essentially unknown for most specific infections.⁵ Infectious diseases are associated with a high number of variables that affect treatment outcome (microbial characteristics and drug sensitivity, diverse resistance mechanisms, tissue barriers to

antibiotic diffusion, and the integrity and activity of the host's defense mechanisms). However, basic principles are available to guide the dental health care provider in establishing proper dosages, dosing intervals and duration of therapy once the microbial pathogen(s) is suspected or identified and a rational choice of antimicrobial agent is made.

The following principles of antibiotic dosing are adapted from Dr. Thomas J. Pallasch⁵:

1. The current recommendation is to employ an antimicrobial on an intensive basis with vigorous dosage for as short a period of time as the clinical situation permits. The major factor in the clinical success of most antimicrobial agents is the height of the serum concentration of the drug and the resulting amount in the infected tissue(s). Also important is to expose the host to the antimicrobial agent for as short a duration of therapy as possible. The shorter the duration of therapy the lower the risk to the patient for the development of antibiotic-induced toxicity and/or allergy, and a reduced risk of developing resistant microorganisms.

2. The goal of antibiotic dosing is to achieve drug levels in the infected tissue equal to or exceeding the minimal inhibitory concentration of the target organism. Serum levels of antibiotics do not necessarily reflect those in tissues. Blood concentrations of the antibiotic should exceed the MIC by a factor of two to eight times in order to offset the tissue barriers that restrict access of the drug to the infected site.

3. It is advisable to initiate antibiotic therapy with a loading dose (an initial dose higher than the maintenance dose). An antibiotic loading dose should be used whenever the

half-life of the drug is longer than three hours or whenever a delay of 12 hours or longer to achieve a therapeutic blood level is expected. Most antibiotics used in the treatment of orofacial infections have a half-life shorter than three hours but, due to their acute nature, most orofacial infections require therapeutic drug blood levels sooner than 12 hours. Steady-state blood levels of any drug are usually achieved in a time equal to three to five times the drug's half-life. Amoxicillin has a half-life of one to one-and-a-half hours. A steady-state blood level would then be achieved in three to seven-and-a-half hours, thereby leading to a substantial delay in achieving therapeutic antibiotic blood levels. A loading dose of two times the maintenance dose is recommended for acute orofacial infections, which better achieves the goal of rapid, high blood levels rather than initiating therapy with the maintenance dose.

4. An oral antibiotic should ideally be administered at dosing intervals of three to four times its serum half-life, particularly if steady-state blood levels are desired (as may be indicated with beta-lactam agents). For example, the serum half-life of Pen-V-K is 0.75 hours. Higher continuous blood levels of this antibiotic are more likely to be obtained with four-hour rather than six-hour dosing intervals. The shorter the serum half-life of the drug, the shorter the dosing interval will need to be in order to maintain continuous therapeutic blood levels of the drug. When determining the appropriate dosing interval, it is also important to consider the following: 1) The postantibiotic effects of the drug; and 2) the relative merits of continuous or pulse dosing. PAEs are more persistent (two to seven hours) with antibiotics that act intra-

Patients at Potential Risk of Experiencing Hematogenous Total Joint Infection ¹⁹	
Patient Type	Condition Placing Patient at Risk
All patients during first two years following joint replacement	N/A
Immunocompromised/immunosuppressed patients	Inflammatory arthropathies such as rheumatoid arthritis, systemic lupus erythematosus Drug or radiation-induced immunosuppression
Patients with comorbidities	Malnutrition Hemophilia HIV infection Insulin-dependent (type 1) diabetes Malignancy

Table 4. (Tables/Provided by American Association of Endodontists)

cellularly within the microbial cytoplasm (erythromycin, clindamycin and tetracycline) or by suppression of nucleic acid synthesis (metronidazole, quinolones). As a result, these antibiotics are more effective with pulse dosing (high antibiotic dosing at widely spaced intervals). The beta-lactam antibiotics, however, have a slow, time-dependent killing activity and demonstrate very little PAE. Beta-lactam microbial killing requires microbes in the process of cell division (interference with cell wall development); hence, they must be continuously present (steady-state blood levels) because bacteria divide at different rates or times.

Myth No. 8: Bacterial infections require a "complete course" of antibiotic therapy. There is no such thing as a "complete course" of antibiotic therapy.⁵ The only guide for determining the effectiveness of antibiotic therapy, and hence, the duration of treatment, is the clinical improvement of the patient.¹⁶ A common misconception asserts that prolonged (after clinical remission of the disease) antibiotic therapy is necessary to prevent "rebound" infections from occurring. Orofacial infections do not "rebound" if the source of the infection is properly eradicated. Most orofacial infections persist for two to seven days, and often less. Patients placed on antibiotic therapy for an orofacial infection should be clinically evaluated on a daily basis. When there is sufficient clinical evidence that the patient's host defenses have regained control of the infection and that the infection is resolving or resolved, the antibiotic therapy should be terminated.

Antibiotic prophylaxis for medically at-risk patients

Antibiotic prophylaxis is the administration of antibiotics to patients without evidence of infection to prevent bacterial colonization and reduce subsequent postoperative or post-treatment complications. The only established use of antibiotic prophylaxis in dentistry is in the attempt to reduce the potential consequences of bacteremia induced by dental treatment in certain medically at-risk patients. The principle indication for antibiotic prophylaxis for dental patients is the prevention of infective endocarditis during specified dental treatment of patients who also have specific medical conditions. Controversial indications include dental patients with orthopedic prosthetic devices, indwelling catheters and impaired (immunosuppressed) host defenses.

Dental patients presenting for treatment with impaired host defenses (chemotherapy, organ transplant or tissue graft recipient, insulin-dependent diabetes, alcoholics) or patients with indwelling catheters (hemodialysis) may benefit from antibiotic prophylaxis if their white cell count is below 2,500 (normal = 4,000-11,000). It is not currently recommended that patients with AIDS receive routine antibiotic prophylaxis prior to dental treatment. The opportunistic pathogens common to this disorder are not susceptible to routine prophylactic antibiotics and such a practice may result in the development of antibiotic-resistant microorganisms, thereby resulting in a serious superinfection.⁵

Antibiotic prophylaxis for prevention of infective endocarditis

The American Heart Association has published guidelines for the prevention of IE in medically at-risk patients for more than 50 years. The most recent guidelines, published in April 2007, represent a significant change from the previous guidelines.¹⁷ One of the stated reasons for the development of the current revised guidelines was that the risk of antibiotic-associated adverse events exceeds the benefit, if any, from prophylactic therapy (Table 1). It is well accepted that the risk for developing bacterial resistant strains to the antibiotic drug used is considered an antibiotic-associated adverse event. The majority of published studies regarding IE being caused by oral bacteria have focused on dental procedures. Although the infective dose required to cause IE in humans is unknown, the number of microorganisms present in the blood following a dental procedure is low. It has long been assumed that dental procedures may cause IE in patients with underlying cardiac risk factors and that antibiotic prophylaxis is effective. However, scientific proof is lacking to support this assumption. Cases of IE caused by oral bacteria probably result more from exposures to low inocula of bacteria in the bloodstream that result from routine daily activities (brushing and flossing) and not from a dental procedure.¹⁷

The 2007 AHA report regarding prevention of IE concludes: "If prophylaxis is effective, such therapy should be restricted to those patients with the highest

Suggested Patient Type, Drug and Regimen for Antibiotic Prophylaxis for Total Prosthetic Joint Infection		
Patient Type	Drug	Regimen*
Patients not allergic to penicillin	Cephalexin, cephadrine or amoxicillin	2g orally 1 hour prior to dental procedure
Patients not allergic to penicillin and unable to take oral medication	Cefazolin or ampicillin	Cefazolin 1g or ampicillin 2g IM or IV 1 hour prior to dental procedure
Patients allergic to penicillin	Clindamycin	600mg orally 1 hour prior to dental procedure
Patients allergic to penicillin and unable to take oral medication	Clindamycin	600mg IV 1 hour prior to dental procedure

Table 1. (Tables/Provided by American Association of Endodontists)



< Page 8

risk of adverse outcomes from IE and who would derive the greatest benefit from prevention. In patients with underlying cardiac conditions associated with the highest risk of adverse outcomes from IE, prophylaxis for some dental procedures is reasonable, even though we acknowledge that its effectiveness is unknown.¹⁷

Therefore, the 2007 AHA guidelines suggest that antibiotic prophylaxis should be considered for patients presenting for treatment with the cardiac conditions identified in Table 2, and who are undergoing any dental procedure that involves the gingival tissues or periapical region of a tooth and for those procedures that perforate the oral mucosa. This would include procedures such as biopsies, suture removal, placement of orthodontic bands, and intraligamentary and intraosseous local anesthetic injections, but it does not include routine local anesthetic injections through noninfected tissue (Table 3).

Antibiotic prophylaxis for prevention of delayed prosthetic joint infection

In 1997, the ADA and the American Academy of Orthopedic Surgeons convened an expert panel of dentists, orthopedic surgeons and infectious disease specialists and published an Advisory Statement on Antibiotic Prophylaxis for dental patients with prosthetic joints.¹⁸ A 2005 advisory statement included some modifications of the classification of patients at potential risk and the stratification of bacteremic dental procedures (Table 4), but no changes in terms of suggested antibiotics or antibiotic regimens.¹⁹ Antibiotic prophylaxis is not indicated for most dental patients with total joint replacements or for patients with pins, plates or screws. However, it is advised to consider antibiotic premedication in a small number of patients who may be at potential increased risk of experiencing hematogenous total joint infection (Table 5).

While bacteremias can cause hematogenous seeding of total joint implants, it is likely that more oral bacteremias are spontaneously induced by routine daily events than are dental treatment-induced. Patients who have undergone total joint arthroplasty should be encouraged to perform effective daily oral hygiene procedures in order to maintain good oral health. The risk of bacteremia is much higher in a mouth with chronic inflammation than one that is healthy and well maintained.

Occasionally, a patient with a total joint prosthesis may present for dental treatment with a recommendation from his or her physician that is inconsistent with the current guidelines. In this case, the dentist is encouraged to consult with the patient's physician to discuss the nature of the needed dental treatment, to review the current guidelines regarding antibiotic prophylaxis and to determine if there are any special considerations that might affect the

physician's decision regarding antibiotic prophylaxis for the patient. After this consultation, the dentist may decide to follow the physician's recommendation or, if in his or her professional judgment antibiotic prophylaxis is not indicated, decide to proceed with the needed dental treatment without antibiotic prophylaxis. The dentist is ultimately responsible for making treatment decisions for his or her patient based on the dentist's professional judgment.

In February 2009, the AAOS published an information statement in which the organization, "recommends that clinicians consider antibiotic prophylaxis for all total joint replacement patients prior to any invasive procedure that may cause bacteremia."²⁰ In response to this statement, the American Academy of Oral Medicine published a position paper in the June 2010 edition of the Journal of the American Dental Association.²¹

The authors of the AAOM position paper stated that they reviewed the available literature on the subject as it relates to the AAOS 2009 information statement and concluded: "The risk of patients' experiencing drug reactions or drug-resistant bacterial infections and the cost of antibiotic medications alone do not justify the practice of using antibiotic prophylaxis in (all) patients with prosthetic joints." The authors called for a future multidisciplinary, systematic review of the literature relating to antibiotic prophylaxis use in patients with prosthetic joints. In the meantime, they concluded that the new AAOS 2009 information statement²⁰ should not replace the 2005 joint consensus statement.¹⁹

In December 2012, a panel of experts representing the American Academy of Orthopedic Surgeons and the American Dental Association published a systematic review and clinical practice guideline, titled "Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures: Evidence-based Guideline and Evidence Report."²⁵ This report contained the following three recommendations:

"The practitioner might consider discontinuing the practice of routinely prescribing prophylactic antibiotics for patients with hip and knee prosthetic joint implants undergoing dental procedures.

"We are unable to recommend for or against the use of topical oral antimicrobials in patients with prosthetic joint implants or other orthopedic implants undergoing dental procedures. "In the absence of reliable evidence linking poor oral health to prosthetic joint infections, it is the opinion of the work group that patients with prosthetic joint implants or other orthopedic implants maintain appropriate oral hygiene."

The report also stated that the above recommendations "are not intended to stand alone. Treatment decisions should be made in light of all

circumstances presented by the patient. Treatments and procedures applicable to the individual patient rely on mutual communication between patient, physician, dentist and other healthcare practitioners."

In 2014, a panel of experts convened by the American Dental Association Council on Scientific Affairs developed an evidence-based clinical practice guideline on the use of prophylactic antibiotics in patients with prosthetic joints who are undergoing dental procedures. This clinical practice guideline was published in The Journal of the American Dental Association in January 2015 and contained the following recommendation:

"In general, for patients with prosthetic joint implants, prophylactic antibiotics are not recommended prior to dental procedures to prevent prosthetic joint infection. The practitioner and patient should consider possible clinical circumstances that may suggest the presence of a significant medical risk to providing dental care without antibiotic prophylaxis, as well as the known risks of frequent or widespread antibiotic use. As part of the evidence-based approach to care, this clinical recommendation should be integrated with the practitioner's professional judgment and the patient's needs and preferences."²⁴

Summary

Since their discovery eight decades ago, safe systemic antibiotics have revolutionized the treatment of infections, transforming once deadly diseases into manageable health problems. However, the growing phenomenon of bacterial resistance, caused by the use and abuse of antibiotics and the simultaneous decline in research and development of new antimicrobial drugs, is now threatening to take us back to the pre-antibiotic era. Without effective treatment and prevention of bacterial infections, we also risk rolling back important achievements of modern medicine such as major surgery, organ transplantation and cancer chemotherapy.²²

A fundamentally changed view of antibiotics is needed. They must be looked on as a common good, where individuals must be aware that their choice to use an antibiotic will affect the possibility of effectively treating bacterial infections in other people. All antibiotic use, appropriate or not, "uses up" some of the effectiveness of that antibiotic, diminishing our ability to use it in the future. For current and future generations to have access to effective prevention and treatment of bacterial infections as part of their right to health, all of us need to act now. The window of opportunity is rapidly closing.²²

References

1. Health, United States, 2009: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, 2009.

2. Health, United States, 2010: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, April 2010.

3. Pallasch TJ. Pharmacology of Anxiety, Pain and Infection. In: Endodontics. 4th ed. Williams and Wilkins, Malvern, PA, 1994.

4. ADA Council on Scientific Affairs. Combating antibiotic resistance. J Am Dent Assoc 2004;135:484.

5. Nicolle L. Nosocomial Infections. Gale Encyclopedia of Public Health. Macmillan Reference USA, Farmington Hills, MI, 2002.

6. Sweeney LC, Jayshree D, Chambers PA, Heritage J. Antibiotic resistance in general dental practice—a cause for concern. J Antimicrobial Chemotherapy 2004;53:567.

7. Epstein JB, Chong S, Le ND. A survey of antibiotic use in dentistry. J Am Dent Assoc 2000;131:1600.

8. Associated Press. Killer superbug solution discovered in Norway. www.msnbc.com, December 2009.

9. ADA Council on Scientific Affairs. Antibiotic use in dentistry. J Am Dent Assoc 1997;128:648.

10. Wills A. Why we learn from our mistakes. J Cognitive Neuroscience 2007;19:1163.

11. Pallasch TJ. Antibiotic myths and reality. J Cali Dent Assoc 1986;14:65.

12. Baumgartner JC. Microbiology of Endodontic Disease. In: Endodontics. 6th ed. B.C. Decker Inc. Hamilton, Ontario, Canada, 2008.

13. Baumgartner JC, et al. Experimentally induced infection by oral anaerobic microorganisms in a mouse model. Oral Microbiol Immunol 1992;7:255-256.

14. Baumgartner JC, Xia T. Antibiotic susceptibility of bacteria associated with endodontic abscesses. J Endodon 2005;29:44-47.

15. Korzeniowski OM. Effects of antibiotics on the mammalian immune system. Infect Dis Clin NA 1989;3:469.

16. Hessen MT, Kaye D. Principles of selection and use of antimicrobial agents. Infect Dis Clin NA 1989;3:479.

17. Wilson W, Taubert K, et al. Prevention of Infective Endocarditis: Guidelines From the American Heart Association, J Amer Heart Assoc 2007;116:1736-1754.

18. American Dental Association, American Academy of Orthopaedic Surgeons. Advisory statement: Antibiotic prophylaxis for dental patients with total joint replacements. J Amer Dent Assoc 1997;128:1004-1008.

19. American Dental Association, American Academy of Orthopaedic Surgeons. Advisory statement: Antibiotic prophylaxis for dental patients with total joint replacements. J Amer Dent Assoc 2005;134:895-898.

20. American Academy of Orthopaedic Surgeons. Information statement: Antibiotic prophylaxis for bacteremia in patients with joint replacements. www.aaos.org. 2010.

21. Little JW, et al. The dental treatment of patients with joint replacements: A position paper from the American Academy of Oral Medicine. J Amer Dent As-

soc 2010;141:667-671.

22. Cars, O. Meeting the challenge of antibiotic resistance, BMJ 2008;337:726-728.

23. American Association of Orthopedic Surgeons and American Dental Association. Prevention of Orthopedic Implant Infections in Patients Undergoing Dental Procedures: Evidence-Based Guideline and Evidence Report. American Academy of Orthopedic Surgeons. December 2012.

24. The Use of Prophylactic Antibiotics Prior to Dental Procedures in Patients with Prosthetic Joints: Evidence-Based Clinical Practice Guideline for Dental Practitioners – A Report of the American Dental Association Council on Scientific Affairs. J Amer Dent Assoc 2015; 146(1):11-16. [DOI](#)

Editorial note: This article originally appeared in ENDODONTICS: Colleagues for Excellence, Winter 2012. Reprinted and updated with permission from the American Association of Endodontists, ©2012. The AAE clinical newsletter is available at www.aae.org/colleagues.

About the Author



Having taught future oral healthcare professionals at Loma Linda University School of Dentistry since 1965, Steven Morrow, DDS, MS, is currently a professor in the department of endodontics that he chaired from 1987 to 1990.

He maintains responsibilities he accepted in 2000 as director of patient care services and clinical quality assurance. He was director, District VI, of the American Association of Endodontists from 1990 to 1995. He has also served as president of the Southern California Academy of Endodontics and as president of the California State Association of Endodontists.

In 1997, he earned diplomate status from the American Board of Endodontics. Since 1998, he has been a fellow of the American College of Dentists; and since 2005, he has served on the editorial review board of the Journal of Endodontics. A life member of the American Dental Association, the American Association of Endodontists and the California State Association of Endodontists, he is currently serving his second term as a member of the Dental Board of California.